**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 39650

**Manuscript Type:** EVIDENCE-BASED MEDICINE

**Comparison of hepatitis C virus testing recommendations in high-income countries**

Irvin R *et al.* Comparison of hepatitis C testing recommendations

Risha Irvin, Kathleen Ward, Tracy Agee, Noele P Nelson, Claudia Vellozzi, David L Thomas, Alexander J Millman

**Risha Irvin, Kathleen Ward, Tracy Agee, David L Thomas,** Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States

**Noele P Nelson, Claudia Vellozzi, Alexander J Millman,** Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30329, United States

**ORCID number:** Risha Irvin (0000-0001-5953-9316); Kathleen Ward (0000-0003-4552-2585); Tracy Agee (0000-0002-9497-5778); Noele P Nelson (0000-0001-9831-0717); Claudia Vellozzi (0000-0003-2797-7551); David L Thomas (0000-0002-0749-925X); Alexander J Millman (0000-0001-5231-1351).

**Author contributions:** Irvin R, Nelson NP, Vellozzi C, Thomas DL and Millman AJ developed the concept and search strategy for the manuscript; Irvin R, Ward K and Agee T performed all relevant data searches; Irvin R, Ward K, Agee T, Nelson NP, Vellozzi C, Thomas DL and Millman AJ reviewed all data obtained from searches and participated in manuscript preparation.

**Supported by** Centers for Disease Control and Prevention, contract No. 200-2013-M-57552; additional support was provided to the primary author by the Johns Hopkins University Center for AIDS Research, No. 1P30AI094189 and NIDA, No. R37DA013806 (to Thomas DL).

**Conflict-of-interest statement:** Dr. Irvin has nothing to disclose. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Risha Irvin, MD, Assistant Professor,** Division of Infectious Diseases, Johns Hopkins University School of Medicine, 725 N Wolfe Street, Room 218A,

Baltimore, MD 21205, United States. [rirvin1@jhmi.edu](mailto:rirvin1@jhmi.edu)

**Telephone:** +1-443-2874843

**Received:** May 5, 2018

**Peer-review started:** May 5, 2018

**First decision:** June 5, 2018

**Revised:** June 27, 2018

**Accepted:** July 9, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate hepatitis C virus (HCV) testing recommendations from the United States and other high-income countries.

***METHODS***

A comprehensive search for current HCV testing recommendations from the top quartile of United Nations Human Development Index (HDI) countries (very high HDI) was performed using Google and reviewed from May 1-October 30, 2014 and re-reviewed April 1-October 2, 2017.

***RESULTS***

Of the 51 countries identified, 16 had HCV testing recommendations from a government body or recommendations issued collaboratively between a government and a medical organization. Of these 16 countries, 15 had HCV testing recommendations that were primarily risk-based and highlight behaviors, exposures, and conditions that are associated with HCV transmission in that region. In addition to risk-based testing, the HCV Guidance Panel (United States) incorporates recommendations for a one-time test for individuals born during 1945-1965 (the birth cohort) without prior ascertainment of risk into their guidance. In addition to the United States, six other countries either have an age-based testing recommendation or recommend one-time testing for all adults independent of risk factors typical of the region.

***CONCLUSION***

This review affirmed the similarities of the HCV Guidance Panel’s guidance with those of recommendations from very high HDI countries.

**Key words:** Hepatitis C; Mass screening; Testing; Recommendations; Guidelines

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This report investigates hepatitis C virus (HCV) testing recommendations from the United States and other high-income countries to assess any risk-based or universal screening categories that should be considered for updates to HCV testing guidance from the HCV Guidance Panel (United States). This review affirmed the similarities of the HCV Panel guidance with those of very high-income countries. No significant gaps in the guidance were identified. HCV testing recommendations from very high-income countries will be continually reviewed and as new risk categories or universal screening recommendations are identified, they will be considered for incorporation into the HCV Panel guidance when peer-reviewed evidence is available to support the incorporation of the HCV testing practices in the United States.

Irvin R, Ward K, Agee T, Nelson NP, Vellozzi C, Thomas DL, Millman AJ. Comparison of hepatitis C virus testing recommendations in high-income countries. *World J Hepatol* 2018; In press

**INTRODUCTION**

Hepatitis C virus (HCV) infection, the leading cause of liver cancer and liver failure, is now curable with the recent emergence of short-duration, non-toxic, all-oral therapies[1-4]. This breakthrough in curative therapies for HCV infection has renewed interest in developing mechanisms to improve the HCV care continuum (testing, linkage to care, treatment initiation, cure). Notably, estimates suggest that 50% of HCV infected individuals remain undiagnosed[5]. Thus, it has become extremely important in infectious disease public health policy to identify the appropriate groups of individuals to test for HCV infection and to have this information readily available to healthcare professionals.

To provide healthcare professionals with a single web-based resource for evidence-based, expert-developed recommendations for hepatitis C testing and management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) formed the HCV Guidance Panel[6]. The HCV Guidance Panel is also supported, in part, by the Centers for Disease Control and Prevention (CDC) and the International Antiviral Society United States (IAS-USA). The guidance published by the HCV Guidance Panel (the HCV Panel guidance) are updated periodically as new evidence is reviewed, including any updates to formal recommendations from the CDC and United States Preventive Services Task Force (USPSTF)[6-8]. In preparation for making updates to the HCV Panel guidance, HCV testing recommendations from the top quartile of United Nations Human Development Index (HDI) countries were evaluated for similarities and differences[9]. These data have been used periodically by the HCV Guidance Panel to explore HCV testing recommendations globally for comparison to the United States and for consideration in updating the HCV Panel guidance when additional peer-review data is available to support the inclusion of the category in the United States. For example, the periodic reviews of global HCV testing recommendations have served to inform discussion on categories that are not included in the HCV Panel guidance. Any new categories for consideration by panel members are reviewed and literature searches are conducted to ensure that the panel addresses all relevant data on the subject[6]. Each guidance statement is then rated in terms of the level and strength of evidence[6].

**MATERIALS AND METHODS**

The HDI is a summary measure of average achievement in health, education, and gross national income per capita[9]. Fifty-one countries including the United States were identified as having a very high HDI, defined as the top quartile of HDI countries[9]. A comprehensive search for current HCV testing recommendations from the top quartile of HDI countries was performed using a Google search with a combination of free text terms. Relevant terms included: country name, hepatitis C, HCV, screening, testing, recommendations, and guidelines. The Google results were then reviewed with experts in the field of hepatitis C (including email and in-person interviews) inquiring about any additional countries known to have HCV testing recommendations.

Testing recommendations were considered if they were from a government body or represented collaborative recommendations between a government and a medical organization. To be included in our analysis, recommendations needed to be available online May 1, 2014-October 2, 2017. Non-English language documents were translated into English using Google Translate. When logical, testing categories were combined to make the tabulation of the results more manageable. Because in the United States both the CDC and USPSTF independently issue HCV testing recommendations, the HCV Guidance Panel’s routine synthesis of these recommendations into their guidance were used for the purpose of this report. From May 1-October 30, 2014, two reviewers performed the initial searches and engaged consultants to identify HCV testing recommendations from very high HDI countries. Two reviewers re-reviewed HCV testing recommendations through Google searches and follow up with expert consults from April 1-October 2, 2017 to identify and update any changes.

**RESULTS**

Of the 51 countries categorized as very high HDI, 16, including the United States were found to have HCV testing recommendations (Table 1)[6,10-26]. Of these 16 countries, 15 had HCV testing recommendations that were primarily risk-based and highlight behaviors, exposures, and conditions that are associated with HCV transmission in that region. In addition to risk-based testing, the HCV Panel guidance incorporates CDC and USPSTF recommendations for a one-time test for individuals born during 1945-1965 (the birth cohort) without prior ascertainment of risk[6-8]. Six additional countries have either an age-based testing recommendation or recommend one-time testing for all adults independent of risk factors. In the United States, individuals born from 1945-1965 are included in both CDC and USPSTF HCV testing recommendations as they account for 75% of all HCV infections and evidence confirmed that a risk-based strategy alone failed to identify more than 50% of HCV infections due to provider and patient barriers in correctly ascertaining risk[6,27].

The HCV Panel guidance recommends one-time testing for all HIV-positive individuals and for any persons about to start pre-exposure prophylaxis (PrEP) for HIV. The HCV Panel guidance also recommends annual HCV testing for persons who inject drugs and for HIV-infected men who have unprotected sex with men.

As of 2017, the HCV testing categories identified in other very high HDI countries not included in the HCV Panel guidance are: (1) Acute hepatitis or hepatitis symptoms; (2) Receiving an immunization or a medical procedure in a specified country or in a country where hepatitis C is common or where universal precautions are not in place; (3) Body piercing or tattoo history; (4) Hemophilia history; (5) Hepatitis A or B infection history; (6) Homeless persons; (7) Immigrants or visitors from countries where HCV is endemic; (8) Liver Cancer; (9) Living with, or sexual partner of, HCV-positive person; (10) Multiple sex partners, history of sexually transmitted infections (STIs), or high risk sexual behaviors; and (11) Attending STI clinic (± any risk factors)

**DISCUSSION**

The HCV Panel guidance is based on epidemiologic data and behaviors, exposures, and conditions associated with acquisition of HCV infection in the United States and are compiled by the expert panel and reviewed regularly[6]. As a result of this initial work in 2014, solid organ donors (deceased and living) were identified as a group not included in the guidance and were thus considered for review. After additional review of the available literature on the subject, donors were added to the HCV Panel guidance in 2014 and given an evidence rating of Class I, Level B[6,28,29]. Prior to this, donors had not been explicitly named as a testing category but were discussed in the text below the testing guidance.

Currently, the HCV Panel guidance include the vast majority of HCV testing recommendation categories noted in other HDI countries and many of the people within risk categories not directly specified would likely receive testing nonetheless because of other associated risks or because of typical clinical care in the United States. For instance, acute hepatitis/hepatitis symptoms, hepatitis A or B history, and liver cancer would prompt a clinical evaluation for hepatitis C and might also be captured by the HCV Guidance Panel category of unexplained chronic liver disease and/or chronic hepatitis including elevated alanine aminotransferase levels[6]. Additionally, hemophilia alone is not recommended for testing by the HCV Guidance Panel; however, certain persons with hemophilia would be tested for HCV because the HCV Panel guidance incorporates recommendations to screen anyone who received blood components before 1992 or clotting factor concentrates produced before 1987 for HCV[6]. The remaining recommendation categories covered by other very high HDI countries but not included in the HCV Panel guidance include: body piercing or tattoo history; being homeless; living with, or the sexual partner of, an HCV-positive person; multiple sex partners, history of STIs, or high risk sexual behaviors; STI clinic populations; and immigrants/visitors from countries were HCV is endemic or those vaccinated or receiving medical procedures in those countries or where universal precautions are not in place. Although body piercings and tattoos are not specifically mentioned in the HCV Panel guidance, they do incorporate recommendations to test persons with percutaneous/parenteral exposures in an unregulated setting[6]. Hence, according to the HCV Guidance Panel, individuals with body piercings/tattoos obtained outside of licensed parlors should undergo HCV testing. Furthermore, this practice would also likely capture medical procedures where strict infection control may not have been followed, both domestically and internationally. While the higher prevalence of HCV in homeless populations is acknowledged by the HCV Guidance Panel, the homeless are not specifically named as a group for testing at this time. Although several studies have noted prevalence rates above 10% in several homeless populations in the United States, it is believed that the risk is often due to high rates of substance use disorders, which would be captured by the HCV Panel guidance to test injection and intranasal drug users[30]. Sexual transmission of HCV is generally considered inefficient except among HIV-infected MSM; therefore, guidance related to sexual transmission categories for the general United States population have not been included as an HCV testing category[31]. STI clinics are also not currently included in the HCV Panel guidance. Data suggest that STI clinic populations have higher prevalence rates of HCV infection than the general population due to overlapping risk factors of sexually transmitted infections and hepatitis C[32,33]. However, the higher prevalence of HCV infection in STI clinic populations is often attributed to the birth cohort (individuals born between 1945 and 1965) and injection drug use, risk groups captured elsewhere in the guidance[32-35]. Finally, while the HCV Guidance Panel continues to review evidence on immigrants/visitors from countries where HCV is endemic, any future guidance for HCV testing among foreign-born individuals would need to account for geographic disparities in HCV prevalence and practicalities in implementing this in clinical practice settings[36,37]. As an example of how this might be implemented, in 2008 the CDC recommended hepatitis B screening for persons born in regions of high and intermediate HBV endemicity (HBsAg prevalence > 2%)[38].

Our report has the following limitations. Our search methodology may have missed recommendations and/or classified recommendations incorrectly from some very high HDI countries due to search terms not capturing relevant information in different languages, recommendations not being accessible on the Internet at the time of the searches, or misinterpretation of the role of the government’s involvement in development of the recommendations. Additionally, some governments may rely on international or national organizations for recommendations on hepatitis C testing without publishing their own recommendations.

This review affirmed the similarities of the HCV Panel guidance with those of very high HDI countries. No significant gaps in the guidance were identified. HCV testing recommendations from very high HDI countries will be continually reviewed and as new risk categories or universal screening recommendations are identified, they will be considered for incorporation into the HCV Panel guidance when peer-reviewed evidence is available to support the incorporation of the HCV testing practices in the United States.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatitis C virus (HCV) infection, the leading cause of liver cancer and liver failure, is now curable with the recent emergence of short-duration, non-toxic, all-oral therapies. This breakthrough in curative therapies for HCV infection has renewed interest in developing mechanisms to improve the HCV care continuum (testing, linkage to care, treatment initiation, cure). This renewed interest in HCV has led to many countries updating their HCV testing recommendations.

***Research motivation***

The United States HCV Guidance Panel provides healthcare professionals with a single web-based resource for evidence-based, expert-developed recommendations for hepatitis C testing and management. HCV recommendations in countries around the world have been recently updated due to advances in HCV treatment. However, this data is not compiled in a central location. This report investigates HCV testing recommendations from the United States and other high-income countries. In preparation for making updates to the HCV Panel guidance, HCV testing recommendations from the top quartile of United Nations Human Development Index (HDI) countries were evaluated for similarities and differences.

***Research objectives***

The main objective of this study was to identify HCV testing recommendations from the top quartile of United Nations HDI countries. The identified HCV recommendations were evaluated for similarities and differences. These data have been used periodically by the HCV Guidance Panel to explore HCV testing recommendations globally for comparison to the United States for consideration in updating the HCV Panel guidance when additional peer-review data is available to support inclusion of the category in the United States.

***Research methods***

A comprehensive search for current HCV testing recommendations from the top quartile of HDI countries was performed using a Google search with a combination of free text terms. Relevant terms included: country name, hepatitis C, HCV, screening, testing, recommendations, and guidelines. The Google results were then reviewed with experts in the field of hepatitis C (including email and in-person interviews) inquiring about any additional countries known to have HCV testing recommendations. Testing recommendations were considered if they were from a government body or represented collaborative recommendations between a government and a medical organization. To be included in our analysis, recommendations needed to be available online May 1, 2014-October 2, 2017. From May 1-October 30, 2014, two reviewers performed the initial searches and engaged consultants to identify HCV testing recommendations from very high HDI countries. Two reviewers re-reviewed HCV testing recommendations through Google searches and follow up with expert consults from April 1-October 2, 2017 to identify and update any changes.

***Research results***

Of the 51 countries identified, 16 had HCV testing recommendations from a government body or recommendations issued collaboratively between a government and a medical organization. Of these 16 countries, 15 had HCV testing recommendations that were primarily risk-based and highlight behaviors, exposures, and conditions that are associated with HCV transmission in that region. In addition to risk-based testing, the HCV Guidance Panel (United States) incorporates recommendations for a one-time test for individuals born during 1945-1965 (the birth cohort) without prior ascertainment of risk into their guidance. In addition to the United States, six other countries either have an age-based testing recommendation or recommend one-time testing for all adults independent of risk factors typical of the region.

***Research conclusions***

This review affirmed the similarities of the HCV Guidance Panel’s guidance with those of recommendations from very high HDI countries. As a result of this initial work in 2014, solid organ donors (deceased and living) were identified as a group not included in the guidance and were thus considered for review. After additional review of the available literature on the subject, donors were added to the HCV Panel guidance in 2014 and given an evidence of rating of Class I, Level B. Prior to this, donors had not been explicitly named as a testing category but were discussed in the text below the testing guidance.

***Research perspectives***

HCV testing recommendations from very high HDI countries will be continually reviewed and as new risk categories or universal screening recommendations are identified, they will be considered for incorporation into the HCV Panel guidance when peer-reviewed evidence is available to support the incorporation of the HCV testing practices in the United States.

**ACKNOWLEDGEMENTS**

The authors would like to thank the HCV Guidance Panel, the American Association for the Study of Liver Diseases, the Infectious Diseases Society of America, the International Antiviral Society United States, the Centers for Disease Control and Prevention, the Johns Hopkins Division of Infectious Diseases, and all expert consults involved in this work.

**REFERENCES**

1 **Centers for Disease Control and Prevention**. HIV and Viral Hepatitis 2016. Available from: URL: http://www.cdc.gov/hiv/pdf/library\_factsheets\_hiv\_and\_viral\_hepatitis.pdf

2 **Alqahtani S**, Sulkowski M. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. *Gastroenterol Clin North Am* 2015; **44**: 825-843 [PMID: 26600222 DOI: 10.1016/j.gtc.2015.06.001]

3 **Alqahtani SA**, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. *Hepatology* 2015; **62**: 25-30 [PMID: 25963890 DOI: 10.1002/hep.27890]

4 **Foster GR**, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. *N Engl J Med* 2015; **373**: 2608-2617 [PMID: 26575258 DOI: 10.1056/NEJMoa1512612]

5 **Yehia BR**, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. *PLoS One* 2014; **9**: e101554 [PMID: 24988388 DOI: 10.1371/journal.pone.0101554]

6 **American Association for the Study of Liver Diseases**. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C 2016. Available from: URL: http://hcvguidelines.org/

7 **Centers for Disease Control and Prevention**. Testing Recommendations for Hepatitis C Virus Infection 2015. Available from: URL: https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm

8 **U.S. Preventive Services Task Force**. Hepatitis C: Screening 2013. Available from: URL: https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-c-screening

9 **United Nations Development Programme**. Human Development Report 2016. Available from: URL: http://hdr.undp.org/en/2016-report

10 **Ministerio De Sanidad, Servicios Sociales E Igualdad**.Hepatitis Virales 2016. Available from: URL: http://www.msal.gob.ar/images/stories/bes/graficos/0000000780cnt-2016-09\_hepatitis-virales-equipos-de-salud.pdf

11 **National HCV Testing Policy Expert Committee (Australian Government Department of Health)**. National Hepatitis C Testing Policy Commonwealth of Australia2017. Available from: URL: http://testingportal.ashm.org.au/images/HCV/HCV\_TESTING\_POLICY\_Mar\_2017.pdf

12 **Grad R**, Thombs BD, Tonelli M, Bacchus M, Birtwhistle R, Klarenbach S, Singh H, Dorais V, Holmes NM, Martin WK, Rodin R, Jaramillo Garcia A; Canadian Task Force on Preventive Health Care. Recommendations on hepatitis C screening for adults. *CMAJ* 2017; **189**: E594-E604 [PMID: 28438952 DOI: 10.1503/cmaj.161521]

13 **The College of Family Physicians of Canada**, Public Health Agency of Canada. Primary Care Management of Hepatitis C 2009. Available from: URL: http://www.cfpc.ca/uploadedFiles/Resources/Resource\_Items/HEP\_C\_Guide\_eng\_2.pdf

14 **Ministerio de Salud de Chile**. Guía Clínica Auge Manejo Y Tratamiento De La Infección Crónica Por Virus De La Hepatitis C (VHC) 2015. Available from: URL: http://web.minsal.cl/wp-content/uploads/2016/04/GUIA-VHC.-2015-Editada.pdf

15 **Denmark National Board of Health**. Guidance on HIV (human immunodeficiency virus) and hepatitis B and C virus 2013. Available from: URL: https://sundhedsstyrelsen.dk/~/media/AD9E0753B12546B8AEA323BF02AC3D2C.ashx

16 **Social and Health Ministry of Finland**. Suomen C-hepatiittistrategia 2017-2019, 2016. Available from: URL: https://julkaisut.valtioneuvosto.fi/handle/10024/78923

17 **Ministère des Affaires sociales et de la Santé**. Management of Persons with Hepatitis B or C Virus Infection 2014. Available from: URL: http://www.afef.asso.fr/ckfinder/userfiles/files/actualites/veille/French-report-Dhumeaux.pdf

18 **Greece Ministry of Health**. National Action Plan for the confrontation of Hepatitis C 2017. Available from: URL: http://www.moh.gov.gr/articles/ministry/grafeio-typoy/press-releases/4865-ethniko-sxedio-drashs-gia-thn-antimetwpish-ths-hpatitidas-c

19 **Inclusion HNS**. Feidhmeannacht na Seirbhise Slainte Health Service Executive. National Hepatitis C Strategy 2011-2014. 2012. Available from: URL: http://www.lenus.ie/hse/handle/10147/243033

20 **Istituto Superiore Di Sanità**. Lo screening per infezione da virus dell'epatite C negli adulti in Italia 2005. Available from: URL: http://www.iss.it/binary/publ/cont/06-47.1171283608.pdf

21 **Ministry of Health Labour and Welfare**. Basic guidelines for promotion of control measures for hepatitis 2011. Available from: URL: http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/hourei-17e.pdf

22 **Ministerio De Sanidad Servicios Sociales E Igualdad**. Plan Estratégico Para El Abordaje De La Hepatitis C En El Sistema Nacional De Salud 2015. Available from: URL: https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan\_estrategico\_hepatitis\_C.pdf

23 **Fretz R**, Negro F, Bruggmann P, Lavanchy D, De Gottardi A, Pache I, Masserey Spicher V, Cerny A. Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection. *Swiss Med Wkly* 2013; **143**: w13793 [PMID: 23740193 DOI: 10.4414/smw.2013.13793]

24 **National Institute of Health and Care Excellence**. Hepatitis B and C Testing 2012. Available from: URL: https://www.nice.org.uk/guidance/ph43

25 **National Health Service**. Hepatitis C Quick reference guide for primary care 2015. Available from: URL: http://www.nhs.uk/hepatitisc/SiteCollectionDocuments/pdf/Hepatitis\_C\_quick\_reference\_for\_PC\_April2011.pdf

26 **МACOM**. Recommendations for diagnosis and treatment of adults with hepatitis C 2017. Available from: URL: http://www.iia-rf.ru/upload/iblock/6d9/6d96c71786128fcab695c11afea3338c.pdf

27 **Smith BD**, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. *MMWR Recomm Rep* 2012; **61**: 1-32 [PMID: 22895429]

28 **Lai JC**, Kahn JG, Tavakol M, Peters MG, Roberts JP. Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis. *Am J Transplant* 2013; **13**: 2611-2618 [PMID: 24034208 DOI: 10.1111/ajt.12429]

29 **Seem DL**, Lee I, Umscheid CA, Kuehnert MJ. Excerpt from PHS guideline for reducing HIV, HBV and HCV transmission through organ transplantation. *Am J Transplant* 2013; **13**: 1953-1962 [PMID: 23890284 DOI: 10.1111/ajt.12386]

30 **Noska AJ**, Belperio PS, Loomis TP, O'Toole TP, Backus LI. Prevalence of Human Immunodeficiency Virus, Hepatitis C Virus, and Hepatitis B Virus Among Homeless and Nonhomeless United States Veterans. *Clin Infect Dis* 2017; **65**: 252-258 [PMID: 28379316 DOI: 10.1093/cid/cix295]

31 **Schmidt AJ**, Falcato L, Zahno B, Burri A, Regenass S, Müllhaupt B, Bruggmann P. Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection? *BMC Public Health* 2014; **14**: 3 [PMID: 24393532 DOI: 10.1186/1471-2458-14-3]

32 **Falade-Nwulia O**, Mehta SH, Lasola J, Latkin C, Niculescu A, O'Connor C, Chaulk P, Ghanem K, Page KR, Sulkowski MS, Thomas DL. Public health clinic-based hepatitis C testing and linkage to care in Baltimore. *J Viral Hepat* 2016; **23**: 366-374 [PMID: 26840570 DOI: 10.1111/jvh.12507]

33 **Thomas DL**, Cannon RO, Shapiro CN, Hook EW 3rd, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. *J Infect Dis* 1994; **169**: 990-995 [PMID: 8169429 DOI: 10.1093/infdis/169.5.990]

34 **Subiadur J**, Harris JL, Rietmeijer CA. Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado. *Public Health Rep* 2007; **122** Suppl 2: 12-17 [PMID: 17542447 DOI: 10.1177/00333549071220S203]

35 **Zimmerman R**, Finley C, Rabins C, McMahon K. Integrating viral hepatitis prevention into STD clinics in Illinois (excluding Chicago), 1999-2005. *Public Health Rep* 2007; **122** Suppl 2: 18-23 [PMID: 17542448 DOI: 10.1177/00333549071220S204]

36 **Ditah I**, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, Luma HN, Charlton M. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. *J Hepatol* 2014; **60**: 691-698 [PMID: 24291324 DOI: 10.1016/j.jhep.2013.11.014]

37 **Averhoff FM**, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. *Clin Infect Dis* 2012; **55** Suppl 1: S10-S15 [PMID: 22715208 DOI: 10.1093/cid/cis361]

38 **Weinbaum CM**, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. *MMWR Recomm Rep* 2008; **57**: 1-20 [PMID: 18802412]

**P-Reviewer:** Abushady EAE, Bouare N, Chen EQ, Luo GH, Milovanovic T **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B, B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Hepatitis C virus testing recommendations from the top quartile of human development index countries**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Countries and approving bodies** | Year Recommendations approved | Abnormal Aminotransferases | Acute hepatitis or hepatitis symptoms | Being immunized/receiving a  medical procedure  in a specified country where  hepatitis C is common or lack of universal precautions | Birth cohort/age recommendations or one-time testing for all | Blood/clotting factor transfusion  Patients/ Transplant Patients | Body Piercing or Tattoo History | Children born to HCV-infected  mothers (expectant mothers) | Chronic liver disease, cirrhosis,  or fibrosis | Contact tracing /exposure to infected blood, shared hygiene materials with HCV + person | Donors - blood, blood product,  tissue or organ | Drug users - injecting | Drug users - intranasal | Healthcare workers (public safety) at risk and/or post-exposure | Hemodialysis history or repeated  percutaneous injections | Hemophilia history | Hepatitis A or B history (or non-A/non-B hepatitis) | HIV-positive patients | Homeless | Immigrants or visitors from countries  where HCV is endemic | Incarceration history alone or with additional risk factors | Liver cancer | Living with or sexual partner of  HCV-positive person | MSM, limited to HIV + MSM (with or without unprotected sex), or sexually active starting PrEP | Multiple Sex Partners, history of STIs, or high risk sexual behaviors | Patient request, percutaneous-parenteral exposure, prior positive HCV test | STI clinic (+/- any risk factors) |
| **Argentina**  Dirección de Sida y ETS, Ministerio de Salud de la Nación | 2016  2016 | X | X | X | X | X |  | X |  |  |  | X | X |  | X |  | X | X |  |  |  |  | X |  | X | X |  |
| **Australia**  National HCV Testing Policy Expert Reference Committee | 2016 | X | X |  |  | X | X | X | X | X | X | X |  | X | X |  | X | X |  | X | X | X | X | X |  | X | X |
| **Canada**  Canadian Task Force on Preventive  Health Care | 2017and2009 | X | X | X |  | X | X | X | X | X |  | X | X |  | X | X | X | X | X  X | X | X |  |  |  | X | X |  |
| **Chile**  Ministerio de Salud de Chile (Chilean Ministry of Health) | 2015 | X |  |  | X | X |  | X | X |  |  | X |  | X | X | X |  | X |  |  |  | X | X |  |  |  |  |
| **Denmark**  Sundhedsst-yrelsen (Danish Health Authority) | 2013 | X |  |  |  | X |  | X | X |  |  | X | X | X | X | X | X | X |  | X |  | X |  |  |  |  |  |
| **Finland**  Sosiaali- ja terveysministeriö (Social and Health Ministry) | 2016 |  |  | X | X | X | X | X |  |  | X | X | X |  |  |  |  | X |  | X | X |  |  | X | X |  |  |
| **France** ANRS/AFEF with Ministère des Affaires sociales et de la Santé (Ministry of Social Affairs and Health) | 2014 | X |  | X | X | X | X | X |  | X | X | X | X |  | X |  |  | X |  | X | X |  | X | X |  |  |  |
| **Greece**  Υπουργειο ΥγειαΣ  (Ministry of Health) | 2017 | X |  |  | X | X |  | X |  |  |  | X |  |  | X |  | X | X |  | X | X |  | X |  | X | X |  |
| **Ireland** Feidhmeannacht na Seirbhise Slainte | 2012 | X |  | X |  | X | X | X |  |  | X | X | X | X | X |  | X | X |  | X | X |  | X | X |  | X |  |
| **Italy**  Istituto Superiore di Sanità | 2005 |  |  |  |  | X |  |  |  |  |  | X |  |  | X |  |  |  |  |  |  |  | X |  | X | X |  |
| **Japan**  Ministry of Health, Labour and Welfare | 2011 |  |  |  | X |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Russian Federation**  Министерство здравоохранения  (Ministry of Health) | 2017 |  | X |  |  | X |  | X | X | X | X | X |  | X | X |  | X |  |  |  | X |  | X | X | X |  |  |
| **Spain**  Ministeriode Sanidad, Servicios Socialese Igualdad (Ministry of Health, Social Services and Equality) | 2015 |  |  |  |  | X | X | X |  | X |  | X | X | X | X |  | X | X |  |  | X |  | X | X |  | X |  |
| **Switzerland**  Bundesamt für Gesundheit  (Swiss Federal Office of Public Health) | 2013 | X | X | X |  | X | X | X | X |  |  | X | X | X | X |  | X | X |  | X | X | X | X | X |  | X |  |
| **United Kingdom** NHS and National Inst for Health and Care Excellence | 2015and2012 | X |  | X |  | X | X | X |  |  |  | X |  |  |  |  |  |  | X | X | X |  | X | X |  | X | X |
| **United States** HCV Guidance Panel | 2017 | X |  |  | X | X |  | X | X | X | X | X | X | X | X |  |  | X |  |  | X |  |  | X |  | X |  |

MSM: Men who have sex with men; X denotes that category is advised for testing.